This report reviews the field of bispecific antibodies, artificially engineered antibodies thathave the ability to bind two or more different antigen simultaneously. Historical as well asrecently developed techniques are demonstrated, together with formats in preclinical andclinical development. We studied the field with the future needs of the developers in mind,when it comes to the processes and tools that can be offered by GE Healthcare BiosciencesAB. The development of bispecific antibodies gave rise to new challenges and product-relatedimpurities, which are handled by various methods. We argue for, based on the formats inclinical and preclinical development, that the methods already used to purify monospecificantibodies remain the most successful methods for the purification of bispecific antibodies.This, together with the design strategies that resolve the initial bottle-necks, ensures that theneeds of the developers are met to the same extent as for monoclonal antibodies. The methodsand formats demonstrated here do not represent all that are available or under trial.
Identifer | oai:union.ndltd.org:UPSALLA1/oai:DiVA.org:uu-384685 |
Date | January 2019 |
Creators | Svahn, Carl Fabian, Khan, Anisha, Wahlsten, Amanda, Larsson, Terese, Koivula, Therese, Andersson, Thomas |
Publisher | Uppsala universitet, Institutionen för biologisk grundutbildning, Uppsala universitet, Institutionen för biologisk grundutbildning, Uppsala universitet, Institutionen för biologisk grundutbildning, Uppsala universitet, Institutionen för biologisk grundutbildning, Uppsala universitet, Institutionen för biologisk grundutbildning, Uppsala universitet, Institutionen för biologisk grundutbildning |
Source Sets | DiVA Archive at Upsalla University |
Language | English |
Detected Language | English |
Type | Student thesis, info:eu-repo/semantics/bachelorThesis, text |
Format | application/pdf |
Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0021 seconds